Real-World Experience of Upadacitinib Dosing Reduction in Patients With Moderate Atopic Dermatitis: A Case Series Study in Taiwan

Yang-Yi Chen; Chieh-Hsun  Chen; Cheng-Che Eric  Lan

doi:10.5826/dpc.1403a186

Real-World Experience of Upadacitinib Dosing Reduction in Patients With Moderate Atopic Dermatitis: A Case Series Study in Taiwan

Authors

Yang-Yi Chen Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Chieh-Hsun Chen Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
Cheng-Che Eric Lan Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

Keywords:

atopic dermatitis, upadacitinib, dosing, effectiveness, real-world

References

Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. Mar 2020;36(3):367-376. doi:10.1080/03007995.2019.1699516

Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Jun 5 2021;397(10290):2169-2181. doi:10.1016/s0140-6736(21)00589-4

Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. Jun 5 2021;397(10290):2151-2168. doi:10.1016/s0140-6736(21)00588-2

Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. Sep 1 2021;157(9):1047-1055. doi:10.1001/jamadermatol.2021.3023

Kiiski V, Karlsson O, Remitz A, Reitamo S. High serum total IgE predicts poor long-term outcome in atopic dermatitis. Acta Derm Venereol. Nov 2015;95(8):943-7. doi:10.2340/00015555-2126

Huang TH, Chen YC, Lin SY, et al. Treatment of atopic dermatitis with dupilumab in Taiwan: dynamic changes of IgE levels as a potential response biomarker. Eur J Dermatol. Dec 1 2019;29(6):658-659. doi:10.1684/ejd.2019.3661